Clinical data | |
---|---|
Pronunciation | /ˌfæmˈsaɪkloʊˌvɪər/[1] |
Trade names | Famvir |
AHFS/Drugs.com | Monograph |
MedlinePlus | a694038 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 75–77% |
Protein binding | 20–25% |
Metabolism | Liver, circulation, intestinal wall (to penciclovir) |
Elimination half-life | 2–2.3 hours |
Excretion | Kidney, faecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.713 |
Chemical and physical data | |
Formula | C14H19N5O4 |
Molar mass | 321.337 g·mol−1 |
3D model (JSmol) | |
Melting point | 103 °C (217 °F) |
| |
| |
(verify) |
Famciclovir is a guanosine analogue antiviral drug used for the treatment of various herpesvirus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).
Famciclovir was patented in 1983 and approved for medical use in 1994.[3][4] In 2007, the United States Food and Drug Administration approved the first generic version of famciclovir. Generic tablets are manufactured by TEVA Pharmaceuticals and Mylan Pharmaceuticals.[5][6]